Cancer of Cervix: Clinical Trials

5 trials for Cancer of Cervix, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 unknown. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 3, Unknown 2
Phase 21Completed 1

Follow Cancer of Cervix: new trials by email Literature Review of Cancer of Cervix trials Research Report on Cancer of Cervix

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine], Two dose, Control group - Cancer of Cervix
Phase 2 / Phase 3CompletedInstituto Nacional de Salud Publica, Mexico60002018-05-302021-12-08
The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies
Cognitive intervention, Control group, psycho-physiological intervention - Cancer of Cervix, Ovarian Cancer
Phase 3UnknownRabin Medical Center602008-08-012009-02-17
Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix
NACT, Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling, Inj.Cisplatin - Cancer of Cervix
Phase 3UnknownTata Memorial Hospital6352003-09-042019-09-20
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
Gemcitabine, Cisplatin, Brachytherapy - Cancer of Cervix
Phase 3CompletedEli Lilly and Company5152002-05-012009-08-11
High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix
HIgh Dose Rate Vs Low DOse Rate Brachytherapy - Cancer of Cervix, Cervical Cancer
Phase 3CompletedTata Memorial Hospital7501996-05-012015-05-06

Narrower conditions

Uterine Cervical Neoplasms (5)  ·  Barakat syndrome (1)  ·  Endometrial Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Broader conditions

Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Genital Diseases (5)  ·  Genital Diseases, Female (5)  ·  Genital Neoplasms, Female (5)  ·  Neoplasms by Site (5)  ·  Urogenital Diseases (5)  ·  Urogenital Neoplasms (5)  ·  Uterine Cervical Diseases (5)  ·  Uterine Diseases (5)  ·  Uterine Neoplasms (5)  ·  Neoplasms (4)  ·  Adnexal Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)

Interventions

Control Groups (2)  ·  Brachytherapy (1)  ·  Cisplatin (1)  ·  Gemcitabine (1)  ·  Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)  ·  Neoadjuvant Therapy (1)  ·  Vaccines, Synthetic (1)

Sponsors

Tata Memorial Hospital (2)  ·  Eli Lilly and Company (1)  ·  Instituto Nacional de Salud Publica, Mexico (1)  ·  Rabin Medical Center (1)

Countries

India (3)  ·  Mexico (2)  ·  Argentina (1)  ·  Bosnia and Herzegovina (1)  ·  Israel (1)  ·  Pakistan (1)  ·  Peru (1)  ·  Thailand (1)

Top investigators

Opher Caspi, MD PhD (1)  ·  Shyam K Shrivastava, MD (1)  ·  Shyamkishore J Shrivastava, MD, DNB (RT) (1)  ·  Sudeep Gupta, MD, DM (1)

Results publications

PMID 21444871, PMID 29432076, PMID 41276263